- Home
- LFLY vs HEPA Comparison
LFLY vs HEPA Comparison
Compare LFLY & HEPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFLY
- HEPA
- Stock Information
- Founded
- LFLY 2010
- HEPA 2013
- Country
- LFLY United States
- HEPA United States
- Employees
- LFLY N/A
- HEPA N/A
- Industry
- LFLY Computer Software: Prepackaged Software
- HEPA Biotechnology: Pharmaceutical Preparations
- Sector
- LFLY Technology
- HEPA Health Care
- Exchange
- LFLY Nasdaq
- HEPA Nasdaq
- Market Cap
- LFLY 4.0M
- HEPA 4.7M
- IPO Year
- LFLY N/A
- HEPA N/A
- Fundamental
- Price
- LFLY $1.54
- HEPA $0.68
- Analyst Decision
- LFLY Strong Buy
- HEPA Hold
- Analyst Count
- LFLY 2
- HEPA 1
- Target Price
- LFLY $7.59
- HEPA N/A
- AVG Volume (30 Days)
- LFLY 47.8K
- HEPA 39.0K
- Earning Date
- LFLY 11-07-2024
- HEPA 11-26-2024
- Dividend Yield
- LFLY N/A
- HEPA N/A
- EPS Growth
- LFLY N/A
- HEPA N/A
- EPS
- LFLY N/A
- HEPA N/A
- Revenue
- LFLY $35,868,000.00
- HEPA N/A
- Revenue This Year
- LFLY N/A
- HEPA N/A
- Revenue Next Year
- LFLY N/A
- HEPA N/A
- P/E Ratio
- LFLY N/A
- HEPA N/A
- Revenue Growth
- LFLY N/A
- HEPA N/A
- 52 Week Low
- LFLY $1.32
- HEPA $0.55
- 52 Week High
- LFLY $6.49
- HEPA $4.47
- Technical
- Relative Strength Index (RSI)
- LFLY 39.51
- HEPA 52.88
- Support Level
- LFLY $1.32
- HEPA $0.60
- Resistance Level
- LFLY $1.87
- HEPA $0.68
- Average True Range (ATR)
- LFLY 0.19
- HEPA 0.05
- MACD
- LFLY -0.01
- HEPA 0.00
- Stochastic Oscillator
- LFLY 32.74
- HEPA 87.80
About LFLY Leafly Holdings Inc.
Leafly Holdings Inc operates an online cannabis information resource platform. It offers cannabis retailers and brands subscription-based marketplace listings that provide its cannabis audience with information, reviews, menus, and ordering and delivery options through legal retailers.
About HEPA Hepion Pharmaceuticals Inc.
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.